Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.
äŒæ¥ã³ãŒãALUR
äŒç€ŸåAllurion Technologies Inc
äžå Žæ¥Mar 29, 2021
æé«çµå¶è²¬ä»»è
ãCEOãGaur (Shantanu)
åŸæ¥å¡æ°134
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Mar 29
æ¬ç€Ÿæåšå°11 Huron Dr Ste 200
éœåžNATICK
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœUnited States of America
éµäŸ¿çªå·01760
é»è©±çªå·15086474000
ãŠã§ããµã€ãhttps://www.allurion.com/en
äŒæ¥ã³ãŒãALUR
äžå Žæ¥Mar 29, 2021
æé«çµå¶è²¬ä»»è
ãCEOãGaur (Shantanu)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã